Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Venous Thrombosis 2Venous Thromboembolism 2Lung Neoplasms 2Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Nadroparin × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡